Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.
Cemiplimab is the first treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.